ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoarthritis and synovitis"

  • Abstract Number: 769 • 2013 ACR/ARHP Annual Meeting

    Synovial Wnt and WISP1 Expression Induces Expression Of Cartilage-Degrading Metalloproteinases In The Synovium

    Martijn H. van den Bosch1, Arjen B. Blom1, Sylvia W. Suen2, Anke E. van Erp2, Fons A. van de Loo3, Esmeralda N. Blaney Davidson1, Peter M. van der Kraan3, Peter L. van Lent4 and Wim B. van den Berg5, 1Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 3Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 5Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands

    Background/Purpose: Although many osteoarthritis (OA) patients show significant synovial involvement, consequences are largely unknown. Previously, we found strong upregulation of Wnts 2b and 16 and…
  • Abstract Number: 48 • 2013 ACR/ARHP Annual Meeting

    The In Vivo Role Of Bone Specific EphB4 Receptor Overexpression In Osteoarthritic Synovial Membrane

    Gladys Valverde-Franco1, David Hum1, Bertrand Lussier2, Koichi Matsuo3, Jean-Pierre Pelletier1, Mohit Kapoor1 and Johanne Martel-Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada, 3Laboratory of Cell and Tissue Biology, School of Medicine, Keio University, Tokyo, Japan

    Background/Purpose: Osteoarthritis (OA) is characterized by progressive destruction of all joint tissues including inflammation of the synovial membrane. The histological changes that occur in OA…
  • Abstract Number: 169 • 2013 ACR/ARHP Annual Meeting

    Effects Of Chondroitin Sulfate On The Gene Expression Profile In Interleukin-1β Stimulated Synovial Fibroblast Cells Cultures

    Cécile Lambert1, Jean-Emile Dubuc2, Eulalia Montell3, Josep Verges3 and Yves Henrotin1, 1University of Liège, Bone and Cartilage Research Unit, Liège, Belgium, 2Clinical University Saint Luc, Orthopaedic Department, Bruxelles, Belgium, 3Pre-Clinical R&D Area, Pharmascience Division, BIOIBERICA S.A., Barcelona, Spain

    Background/Purpose: Chondroitin sulfate (CS) is one the most used molecules in the management of OA. Its mechanism of action remains to be detailed. In this…
  • Abstract Number: 1101 • 2012 ACR/ARHP Annual Meeting

    Condroitin Sulfate Decreases Chemokine Levels and Synovitis in knee osteoarthritis Patients

    Jordi Monfort1, Paula Escudero2, Cristobal Orellana3, Laura Piqueras4, Laura Tio5, Francisco Montañés6, Natalia García7, Chantal Company2, Pere Benito8 and Maria Jesús Sanz2, 1Reumatologia, Hospital del Mar, Barcelona, Spain, 2Pharmacology, Universitary Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, 3Rheumatology, Corporació Sanitaria Parc Taulí, Sabadell, Spain, 4University Clinic Hospital Research Foundation-INCLIVA, University of Valencia, Valencia, Spain, 5U.R. Inflamació cel·lular i cartílag, GRICIC. FIMIM, Barcelona, Spain, 6Rhaumatology, Hospital del Mar, Barcelona, Spain, 7GRICIC. FIMIM, Barcelona, Spain, 8Hospital del Mar, Barcelona, Spain

    Background/Purpose: Synovitis is one of the major signs of structure damage in osteoarthritis (OA) progression. Chondroitin sulfate (CS) is an effective drug in the treatment…
  • Abstract Number: 25 • 2012 ACR/ARHP Annual Meeting

    Activation of the Canonical Wnt Signaling Pathway Is Tissue Dependent in Osteoarthritic Joints: Distinct Mechanisms of Regulation by Wnt Antagonists

    Thomas Funck-Brentano1, Wafa Bouaziz1, Hilene Lin1, Valerie Geoffroy1, Eric Hay1 and Martine Cohen-Solal2, 1INSERM U606 Paris 7 university, Paris, France, 2Rhumatologie A, INSERM U606 Hôpital Lariboisière, Centre Viggo Petersen, Paris, France

    Background/Purpose: Wnt signaling pathway is a major regulator of bone and cartilage remodeling. Modulation of this pathway has lead to controversial results on joint cartilage…
  • Abstract Number: 1 • 2012 ACR/ARHP Annual Meeting

    Evaluation of Synovial Inflammation Assessed by Macroscopic and Histological Criteria in Patients with Knee Osteoarthritis

    Montserrat Romera-Baures Sr.1, Ramon Valls-Garcia Sr.2, Antonio Rozadilla Sr.3, Marta Terricabras Sr.4 and Joan Miquel Nolla Sr.5, 1Rheumatology, Hospital Universitari Bellvitge, Barcelona, Spain, 2Rheumatology, Hospital de Palamos, Girona, Palamos (Girona), Spain, 3Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, 4Departament of Pathology, Hospital Universitari de Bellvitge., Barcelona, Spain, 5Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain

    Background/Purpose: Although osteoarthritis (OA) is commonly described as a non-inflammatory joint disease, synovial inflammation is increasingly recognized as contributing to the symptoms and progression of…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology